Form 4: Soleno Therapeutics Merger: Executive Ownership Changes

Meredith Manning, Chief Commercial Officer of Soleno Therapeutics, reports significant changes in beneficial ownership following the company's merger with Neocrine Biosciences.

Summary

• Meredith Manning, Chief Commercial Officer of Soleno Therapeutics Inc., has reported changes in beneficial ownership of company securities.
• These changes are a result of the merger between Soleno Therapeutics, Inc. and Neocrine Biosciences, Inc. (Parent) via Sigma Merger Sub, Inc. (Merger Sub), which became effective on May 18, 2026.
• In connection with the merger, all outstanding shares of Soleno Therapeutics' Common Stock were cancelled and converted into the right to receive $53.00 in cash per share.
• Previously reported restricted stock units (RSUs) were also cancelled and converted into the right to receive the $53.00 cash merger consideration.
• Employee stock options were cancelled in exchange for a cash payment equal to the difference between the merger consideration ($53.00) and the option's exercise price, multiplied by the number of shares covered by the option.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports on the completion of a merger and the resulting cash payouts, which is a definitive event for shareholders but does not provide new operational or financial performance data.

Positives

• The merger provides a cash payout of $53.00 per share for all outstanding common stock, representing a realization event for shareholders.
• Executive stock options were converted into cash payments, providing a financial benefit to option holders based on the merger consideration.

Negatives

• All outstanding common stock was cancelled and converted to cash, meaning no ongoing equity ownership in the merged entity for former Soleno shareholders.
• Employee stock options were cancelled, eliminating potential future upside from equity appreciation beyond the merger consideration.

Risks

• The filing does not explicitly detail risks associated with the merger itself, but the conversion of equity to cash eliminates future participation in potential growth of the combined entity.
• The cash-out nature of the transaction means shareholders and option holders are exposed to the risk of the combined entity's future performance not exceeding the realized cash value.

Future Outlook

The filing primarily reports on past transactions related to a merger. Future outlook for the combined entity is not detailed within this specific Form 4 filing.

Management Comments

• The filing details the cancellation of vested and unvested RSUs into the right to receive $53.00 in cash.
• It also states that each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive $53.00 in cash.
• Employee stock options were cancelled in exchange for a cash payment calculated based on the merger consideration and the option's exercise price.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a common outcome for smaller biotechnology or therapeutics companies acquired by larger entities, where cash-out mergers are prevalent, providing liquidity to early investors and employees but ending the public trading life of the acquired company.

Stakeholder Impact

• Shareholders: Will receive $53.00 in cash per share, realizing their investment but losing future equity participation.
• Employees (with stock options/RSUs): Will receive cash payments based on their vested equity, providing financial benefit but eliminating potential future equity gains.
• Management: As reporting persons, their beneficial ownership is directly impacted by the merger's terms, converting equity holdings into cash.

Next Steps

• Shareholders and option holders will receive cash payments as per the merger agreement.
• Soleno Therapeutics, Inc. will cease to exist as an independent publicly traded entity.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Merger, Neocrine Biosciences, Form 4, Beneficial Ownership, Stock Options, RSUs, Meredith Manning, SEC Filing